Clinical Trial Failure Risk: PHH faces significant risk that its product candidates will fail to demonstrate safety and efficacy in clinical trials, or will not achieve regulatory approval, leading to substantial investment losses and delays.

Intellectual Property Erosion Threat: The company's success relies heavily on its ability to obtain and protect patents and other intellectual property rights; challenges to these rights, or their expiration, could undermine its market position and profitability.

Funding Volatility Impact: As a biotechnology company, PHH requires substantial capital for research, development, and commercialization, and its ability to secure future funding on favorable terms is critical and uncertain.